A growing economy,
large population base, and innovation-friendly environment are other key
parameters that are anticipated to drive the growth of the pharmaceutical
contract manufacturing market in China. Further, in order to meet the growing
demand for their services, CMOs having manufacturing facilities in China are
actively expanding their existing capacities and capabilities in the region.
To order this 200+
page report, which features 85+ figures and 100+ tables, please visit this link
The USD 13 billion
(by 2030) financial opportunity within the pharmaceuticals contract
manufacturing market in China has been analyzed across the following segments:
§
- Eastern
China
- Southern
China
- Northern
China
§
- Active
Pharmaceutical Ingredients (APIs)
- Drug
Products
§
- Solid
- Liquid /
Semi-Solid
- Injectable
- Others
§
- Clinical
- Commercial
§
- Small
- Mid-Sized
- Large / Very
Large
The China Pharmaceutical
Contract Manufacturing Services Market, 2020-2030 report features the
following companies, which we identified to be key players in this domain:
§
§
§
§
§
§
§
§
§
§
§
Table of Contents
1. Preface
4. Case Study: Comparison of Small
Molecules and Large Molecules
5. Market Overview
6. Manufacturing Facilities of Pharmaceutical CMOs
in China
7. Pharmaceutical Manufacturing Regulations in
China
8. Company Profiles
9. Big Pharma Initiatives in China
10. Recent Trends
11. Capacity Analysis
12. SWOT Analysis
13. Market Forecast
14. Case Study: Impact of Coronavirus Outbreak
14. Conclusion
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and
Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com